ReviewPharmaceutics2025
Advancements in Cyclodextrin Complexes with Bioactive Secondary Metabolites and Their Pharmaceutical Applications.
Review in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Decoding Cyclodextrins in Skin Applications: Structure, Mechanisms, and Safety in Cosmetic and Dermatologic Formulations (Part I).International journal of molecular sciences · 2026Review
- β-cyclodextrin and succinic acid-driven metabolic enhancement of lipid, phycobiliprotein, and exopolysaccharide production in Porphyridium purpureum.Bioprocess and biosystems engineering · 2026Article
- Photostability and antimicrobial performance of natural yellow pigments in food systems: Insights into light-induced degradation and functional consequences.Food chemistry: X · 2026Review
- β-Cyclodextrin Inclusion Complexes ofPharmaceutics · 2026Article
- Sustainable Cyclodextrin Modification and Alginate Incorporation: Viscoelastic Properties, Release Behavior, and Morphology in Bulk and Microbead Hydrogel Systems.Gels (Basel, Switzerland) · 2025Article
- Recent Developments in Osteoarthritis Research: Innovative Therapeutic Approaches and the Role of Polyphenols and Nanotechnology.International journal of molecular sciences · 2025Review
- Physicochemical and Computational Study of the Encapsulation of Resv-4'-LA and Resv-4'-DHA Lipophenols by Natural and HP-β-CDs.International journal of molecular sciences · 2025Article
- The Anti-Angiogenic Effect ofFoods (Basel, Switzerland) · 2025Article
- Patent-Based Technological Overview of Propolis-Cyclodextrin Inclusion Complexes with Pharmaceutical Potential.Pharmaceutics · 2025Review
- Neuroprotective Potential of Betulin and Its Drug Formulation with Cyclodextrin-In Vitro Assessment.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclodextrins (CDs) have largely been investigated during the last decades for their outstanding properties, such as biocompatibility and biodegradability, with wide applications in the pharmaceutical field, among which the formation of inclusion complexes (ICs) with natural or synthetic lipophilic compounds. This review prioritizes the research of recent years (2022-2025), being focused on (1) systematization of the research of ICs based on the structure of the secondary metabolite, namely (i) polyphenols (PPs), (ii) terpenes and terpenoids (TTs), and (iii) alkaloids (Alks); (2) for each type of inclusion complex, the following aspects have been discussed: benefits of complexation, composite materials, and in vitro/in vivo and theoretical studies; and (3) pharmacokinetics and pharmacodynamics, risks, limitations, and perspectives of cyclodextrin inclusion complexes with secondary metabolites.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.